Camyotope

Camyotopes are a novel class of shared therapeutic cancer targets derived from the "dark genome," specifically from long non-coding RNA (lncRNA) sequences [1, 3]. Discovered and named by myNEO Therapeutics, these antigens are selectively translated in tumor cells but remain silent in healthy tissues, providing a high degree of tumor specificity [3, 6]. Unlike traditional neoantigens that are often unique to individual patients, camyotopes are highly conserved and shared across more than 95% of patients within specific cancer populations, such as those with colorectal cancer [6, 7]. This conservation enables the development of "off-the-shelf" immunotherapies, including mRNA-based vaccines like CAMYO-01 [1, 5]. These vaccines work by delivering the genetic code for a pool of camyotopes to the patient's immune system, thereby inducing a robust, multi-targeted T-cell response against the tumor [2, 6]. By targeting the non-coding regions of the genome, camyotopes offer a promising strategy for treating cancers with low mutational burdens that typically lack sufficient actionable targets for conventional immunotherapy [2, 6].

Other names

Dark genome antigen [1, 2]lncRNA-derived antigen [1, 3]Tumor-derived epitope from the non-coding genome [1, 6]

Induction of antigen-specific CD4+ and CD8+ T-cell responses through the presentation of lncRNA-derived epitopes on MHC molecules following mRNA-based vaccination [2, 6, 7].